Management Archives - Juvena Therapeutics

Jeremy O’Connell, PhD

As Chief Scientific Officer and Co-Founder of Juvena Therapeutics, Dr. O’Connell oversees research strategy, pre-clinical science and manufacturing, and intellectual property efforts. Dr. O’Connell’s expertise in proteomics and systems biology was accrued during a PhD from UT Austin, a postdoc at Harvard, and his time in industry.

Prior to Juvena Therapeutics, in his postdoctoral fellowship at Harvard Medical school in the lab of Steven Gygi, he leveraged large proteomics datasets to build machine learning classifiers to improve protein-protein interaction predictions within the ubiquitin system.

He has spearheaded research projects in multiple tier-one research institutions, including Harvard and Stanford, employing a combination of mass spectrometry, high throughput imaging, and computational approaches. His work has resulted in numerous peer-reviewed publications, approved and pending patents, millions in award grant funding as the primary PI, fellowships, and awards.

Learn more about Jeremy

PubMed Library
LinkedIn

Back to Careers

Banmeet Anand, PhD

Dr. Banmeet Anand’s more than 20 years experience in the discovery and development of antibodies encompasses fusion proteins, naked, ADCs and bi-specific antibodies; small molecules, and cellular therapies (NK-T, CAR-T) at biotechs and large pharma including Harpoon (a subsidiary of Merck & Co. inc.), Astellas and Genentech.

As senior vice president of drug development Dr. Anand leads development of Juvena’s biological assets including the pre-clinical, non-clinical and IND-enabling studies.

Prior, he served as Senior Vice President of Translational Medicine at Harpoon Therapeutics (a subsidiary of Merck & Co. Inc.) where he led toxicology, pharmacology, biomarkers, non-clinical/clinical PK/PD, companion diagnostics including IND-enabling studies supporting Harpoon’s proprietary TriTAC biologics (T-cell engagers) portfolio. Dr. Anand previously held management and scientific positions at Molecular Templates, NantKwest (ImmunityBio), Astellas (Agensys) and Genentech where he was involved in early and late development of multiple approved drugs such as RITUXAN®, PADCEV® and OCREVUS®.

Dr. Anand received his PhD in Pharmaceutical Sciences and Chemistry from the University of Missouri-Kansas City.

Learn more about Dr. Banmeet Anand

Back to Careers

Colin Hislop, MD

As SVP Clinical Development, Dr. Colin Hislop leads Juvena’s clinical-stage drug candidates. His 36-year tenure in drug development and life sciences spans multinational roles across therapeutic areas at companies including Lilly (formerly Eli Lilly & Company), Proctor & Gamble Pharmaceuticals, Peninsula Therapeutics, Versartis Inc. Anthera Pharmaceuticals and most recently Eiger BioPharnaceuticals. His expertise encompasses early and late-stage clinical development as well as the successful prosecution of multiple drug approvals.

Just prior to Juvena, Dr. Hislop helped lead the successful prosecution of an NDA (2020) and MAA (2022) for lonafarnib to treat an ultra-rare genetic disease called Hutchinson-Guilford Progeria Syndrome. Other roles include Chief Medical Officer at Versartis Inc.; SVP and Chief Medical Officer at Anthera Pharmaceuticals where he served on the leadership team to take the Company public.

Dr. Hislop obtained an undergraduate degree in Medical Biochemistry from the University of Surrey and his medical degree from the Middlesex Hospital Medical School, University of London.

Learn more about Dr. Colin Hislop

Back to Careers

Bek Madjidov

Bek Madjidov is the Head of Finance and Operations at Juvena Therapeutics, responsible for administrative and operational functions (finance, human resources, information technology, and facilities).

Bek is a transformational leader who brings strong business acumen and over 15 years of finance and operations experience in the biotech and high-tech industries. His areas of expertise are strategic planning, business analysis, management reporting, process improvement, and organizational transformation.

Bek previously served as Finance Director at Genentech (Roche), supporting Product Development and Manufacturing Operations organizations. He provided finance leadership to global product and functional teams and led transformational efforts in business and finance organizations. Prior to Genentech, Bek held a variety of finance and leadership roles at Autodesk and Bio-Rad Laboratories by successfully building and leading teams that built strong, cross-functional business partnerships in complex, matrix organizations.

Bek holds a Bachelor of Science (summa cum laude) in Business Administration from the University at Buffalo, State University of New York (SUNY). Bek is pursuing a Master of Business Administration (MBA) from the Haas School of Business at the University of California, Berkeley.

Learn more about Bek

Jeremy O’Connell, PhD

Banmeet Anand, PhD

Colin Hislop, MD

Bek Madjidov

Navigation

Contact

Stay in touch